Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations

Table 2 HCC incidence rates according to clinical setting and geographic areas

Clinicalsetting	Geographicarea	Studies(n)	Patients(n)	Meanfollow-up (yr)	HCCincidence	95% CI
Asympto- matic carrier	North America	2	1804	16	0.1	0.07-0.14
	Taiwan and China	4	18869	8	0.7	0.61-0.70
	Japan	1	513	7.3	0.2	0.08-0.39
Inactive carrier	Europe	3	410	16	0.02	0-0.04
	Taiwan	1	189	8	0.2	0-0.42
Chronic hepatitis	Europe	6	471	5.9	0.1	0-0.27
	Taiwan	2	461	4.0	1.0	0.36-1.56
	Japan	2	737	5.1	0.8	0.46-1.06
Compensated cirrhosis	Europe	6	401	5.8	2.2	1.62-2.80
	Taiwan/ Singapore	3	278	4.3	3.2	1.94-4.55
	Japan	2	306	5.8	4.3	3.40-5.25

Adapted from ref. 101 with permission from American Gastroenterological Association.